HUE043228T2 - Stabil szubmikron peptid vagy protein részecskék képzése vékonyfilm fagyasztással - Google Patents

Stabil szubmikron peptid vagy protein részecskék képzése vékonyfilm fagyasztással

Info

Publication number
HUE043228T2
HUE043228T2 HUE08771657A HUE08771657A HUE043228T2 HU E043228 T2 HUE043228 T2 HU E043228T2 HU E08771657 A HUE08771657 A HU E08771657A HU E08771657 A HUE08771657 A HU E08771657A HU E043228 T2 HUE043228 T2 HU E043228T2
Authority
HU
Hungary
Prior art keywords
peptide
formation
thin film
protein particles
film freezing
Prior art date
Application number
HUE08771657A
Other languages
English (en)
Inventor
Keith Johnston
Joshua Engstrom
Iii Robert O Williams
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of HUE043228T2 publication Critical patent/HUE043228T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
HUE08771657A 2007-06-22 2008-06-20 Stabil szubmikron peptid vagy protein részecskék képzése vékonyfilm fagyasztással HUE043228T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94573707P 2007-06-22 2007-06-22

Publications (1)

Publication Number Publication Date
HUE043228T2 true HUE043228T2 (hu) 2019-08-28

Family

ID=40185998

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE08771657A HUE043228T2 (hu) 2007-06-22 2008-06-20 Stabil szubmikron peptid vagy protein részecskék képzése vékonyfilm fagyasztással

Country Status (8)

Country Link
US (5) US8968786B2 (hu)
EP (1) EP2170283B1 (hu)
JP (1) JP5658031B2 (hu)
CA (1) CA2691531C (hu)
DK (1) DK2170283T3 (hu)
ES (1) ES2717154T3 (hu)
HU (1) HUE043228T2 (hu)
WO (1) WO2009002874A1 (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5658031B2 (ja) 2007-06-22 2015-01-21 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 薄膜凍結による安定したサブミクロンのペプチド又はタンパク質粒子の形成
WO2010056657A2 (en) * 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
US20120251595A1 (en) * 2009-11-09 2012-10-04 Board Of Regents, The University Of Texas System Emulsion template method to form small particles of hydrophobic agents with surface enriched hydrophilicity by ultra rapid freezing
US20130008191A1 (en) * 2011-07-07 2013-01-10 Suchak Naresh J Methods for freezing and thawing proteins
US10183968B2 (en) 2011-10-31 2019-01-22 Merck Sharp & Dohme Corp. Methods of preparing lyophilized spherical-shaped pellets of biological materials
EP2671591B1 (en) 2012-06-08 2017-08-09 Corden Pharma Brussels Process for the preparation of short-chain peptide powders
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
EA201890618A1 (ru) 2015-09-01 2018-10-31 Ферст Вэйв Байо, Инк. Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами
CA3083953A1 (en) 2017-12-11 2019-06-20 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
CN110577567A (zh) * 2019-09-03 2019-12-17 杭州诺泰澳赛诺医药技术开发有限公司 一种制备高比表面积活性多肽或蛋白的方法
TW202200121A (zh) 2020-03-16 2022-01-01 美商費斯特威弗生技股份有限公司 治療方法
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
CN111346572B (zh) * 2020-03-18 2022-06-21 上海理工大学 控制凝固液滴形状的方法及应用
WO2021195765A1 (en) 2020-03-30 2021-10-07 Pulmonem Inc. Dapsone formulations and methods of using same
CA3126367A1 (en) 2020-03-30 2021-09-30 Pulmonem Inc. Dapsone formulations and methods of using same
JP2023520018A (ja) 2020-04-01 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ニクロサミドの薬学的組成物
AU2022271790A1 (en) 2021-05-12 2023-11-23 Tff Pharmaceuticals, Inc. Dry powder formulations of tacrolimus for administration by inhalation once daily (qd)
US20230057155A1 (en) * 2021-08-11 2023-02-23 Board Of Regents, The University Of Texas System Dry liposome formulations and related methods thereof
WO2023034844A1 (en) 2021-08-31 2023-03-09 Board Of Regents, The University Of Texas System Delayed release niclosamide formulation

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795516A (fr) 1972-02-17 1973-08-16 Ciba Geigy Preparations de peptides huileuses et injectables et procede pour leur preparation
US4310516A (en) 1980-02-01 1982-01-12 Block Drug Company Inc. Cosmetic and pharmaceutical vehicle thickened with solid emulsifier
EP0079143A3 (en) 1981-10-20 1984-11-21 Adnovum Ag Pseudoplastic gel transfer
US4594108A (en) 1983-09-19 1986-06-10 The Dow Chemical Company Highly pseudoplastic polymer solutions
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US4704873A (en) * 1985-11-14 1987-11-10 Taiyo Sanso Co., Ltd. Method and apparatus for producing microfine frozen particles
US4848094A (en) * 1988-04-29 1989-07-18 Union Carbide Corporation Droplet freezing method and apparatus
US5288479A (en) 1989-01-17 1994-02-22 Sterling Drug, Inc. Extrudable elastic oral pharmaceutical gel compositions and metered dose dispensers containing them and method of making and method of use thereof
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
SE465950B (sv) 1989-10-23 1991-11-25 Medinvent Sa Kombination av ett aggregat partikelformat, kristallint eller frystorkat laekemedel med en pseudoplastisk gel foer beredning av ett injicerbart preparat samt foerfarande foer dess framstaellning
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5300302A (en) 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
YU87892A (sh) 1991-10-01 1995-12-04 Eli Lilly And Company Lilly Corporate Center Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu
MX9301821A (es) 1992-03-30 1994-03-31 Alza Corp Sistema de matriz polimerica biodegradable regulador de degradacion y metodo de tratamiento del mismo.
AU3941493A (en) 1992-03-30 1993-11-08 Alza Corporation Viscous suspensions of controlled-release drug particles
US5512293A (en) 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
KR100360636B1 (ko) 1994-06-13 2002-12-18 앨자 코포레이션 액체제제내의약물투여용제형
JPH0899897A (ja) 1994-08-05 1996-04-16 Shionogi & Co Ltd インターロイキン−２吸着型脂質小球体
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5916582A (en) 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
IL127769A (en) 1996-07-03 2006-10-31 Alza Corp Non-aqueous protic preparations of peptides
IN184589B (hu) 1996-10-16 2000-09-09 Alza Corp
US7393630B2 (en) 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
ATE322889T1 (de) 1999-02-08 2006-04-15 Alza Corp Stabile nicht wässerige einphasige visköse vehikeln und formulierungen die diese vehikeln verwenden
US20060159756A1 (en) 1999-09-10 2006-07-20 Brita Sjoblom Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
KR20020063853A (ko) * 1999-09-17 2002-08-05 다케다 야쿠힌 고교 가부시키가이샤 단백질 분체의 제조 방법
FR2809309B1 (fr) 2000-05-23 2004-06-11 Mainelab Microspheres a liberation prolongee pour administration injectable
US7374782B2 (en) 2000-10-27 2008-05-20 Baxter International Inc. Production of microspheres
CA2436418A1 (en) * 2001-01-30 2002-08-08 Board Of Regents, The University Of Texas Systems Process for production of nanoparticles and microparticles by spray freezing into liquid
US20040022861A1 (en) * 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
DE60231862D1 (de) 2001-02-23 2009-05-20 Genentech Inc Erodierbare polymere zur injektion
WO2003000014A2 (en) 2001-06-21 2003-01-03 Altus Biologics, Inc. Spherical protein particles and methods of making and using them
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
EP1423096B1 (en) 2001-08-29 2006-08-16 Dow Global Technologies Inc. A process for preparing crystalline drug particles by means of precipitation
WO2004060343A1 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
JP4933732B2 (ja) * 2003-01-15 2012-05-16 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 低温表面上で凍結させることによって得られる薬物粒子
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
BRPI0414970A2 (pt) 2003-06-24 2012-12-11 Baxter Int método para transporte de drogas ao cérebro
MXPA06000720A (es) 2003-07-18 2006-08-23 Baxter Int Metodos para fabricacion, usos y composiciones de particulas esfericas pequenas preparadas por separacion de fase controlada.
WO2005061088A1 (en) * 2003-12-22 2005-07-07 Finlay Warren H Powder formation by atmospheric spray-freeze drying
KR100638041B1 (ko) 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
CA2566075A1 (en) 2004-05-12 2005-12-01 Baxter Healthcare S.A. Microspheres comprising protein and showing injectability at high concentrations of said agent
US20060141040A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20070015689A1 (en) 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
EP1968550A2 (en) 2005-12-16 2008-09-17 University Of Kansas Nanoclusters for delivery of therapeutics
WO2010009146A1 (en) 2008-07-15 2010-01-21 University Of Kansas Nanoclusters for delivery of poorly water soluble drug nanoparticles
WO2007072982A1 (en) 2005-12-20 2007-06-28 Fujifilm Corporation Protein nanoparticles and the use of the same
US20080102128A1 (en) 2006-07-28 2008-05-01 Flamel Technologies, Inc. Modified-release microparticles based on amphiphilic copolymer and on active principles(s) and pharmaceutical formulations comprising them
JP5658031B2 (ja) * 2007-06-22 2015-01-21 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 薄膜凍結による安定したサブミクロンのペプチド又はタンパク質粒子の形成
CN101081882A (zh) 2007-07-06 2007-12-05 天津大学 大分子印迹交联聚乙烯基吡咯烷酮微球及低温悬浮聚合制备方法
JP2009173610A (ja) 2008-01-28 2009-08-06 Fujifilm Corp タンパク質ナノ粒子
EP2259798B1 (en) 2008-03-05 2013-12-11 Baxter International Inc. Surface-modified particles and methods for targeted drug delivery
BRPI0908686B8 (pt) 2008-05-09 2021-05-25 South Dakota State Univ método de produção de nanopartículas não-imunogênicas, nanopartícula não-imunogênica terapeuticamente ativa, composição terapêutica, uso de uma nanopartícula não-imunogênica e kit para a produção de nanopartículas não-imunogênicas
US20100009007A1 (en) 2008-07-10 2010-01-14 Baxter International Inc. Non-covalent modification of microparticles and process of preparing same
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
WO2010056657A2 (en) 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
AR075715A1 (es) 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
US8399406B2 (en) 2009-06-05 2013-03-19 Chiesi Farmaceutici S.P.A. Reconstituted surfactant composition containing analogs of surfactant protein B (SP-B) and surfactant protein C (SP-C)
US20120230913A1 (en) 2011-03-10 2012-09-13 Board Of Regents, The University Of Texas System Protein nanoparticle dispersions
US20160058863A1 (en) 2014-09-03 2016-03-03 Board Of Regents, The University Of Texas System Low viscosity concentrated protein dispersions

Also Published As

Publication number Publication date
US11759427B2 (en) 2023-09-19
CA2691531C (en) 2016-11-01
WO2009002874A1 (en) 2008-12-31
US20100247506A1 (en) 2010-09-30
US10285945B2 (en) 2019-05-14
EP2170283B1 (en) 2019-01-09
EP2170283A1 (en) 2010-04-07
JP5658031B2 (ja) 2015-01-21
ES2717154T3 (es) 2019-06-19
JP2010530899A (ja) 2010-09-16
EP2170283A4 (en) 2013-01-23
CA2691531A1 (en) 2008-12-31
US9622974B2 (en) 2017-04-18
DK2170283T3 (en) 2019-04-15
US20150209289A1 (en) 2015-07-30
US20170360711A1 (en) 2017-12-21
US20190274958A1 (en) 2019-09-12
US8968786B2 (en) 2015-03-03
US10898437B2 (en) 2021-01-26
US20210275457A1 (en) 2021-09-09

Similar Documents

Publication Publication Date Title
HUE043228T2 (hu) Stabil szubmikron peptid vagy protein részecskék képzése vékonyfilm fagyasztással
EP2315833B8 (en) Vectors for delivery of light-sensitive proteins and methods of use
ZA201003131B (en) Anti-rsv g protein antibodies
EP2612856B8 (en) Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
GB0700523D0 (en) The Stabilisation Of Proteins
HK1132754A1 (en) 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
HK1122311A1 (en) Antibodies against amyloid-beta peptide
PT2004155T (pt) Inibidores de agregação proteica
AU2008210434A8 (en) Stabilized p53 peptides and uses thereof
EP2102355A4 (en) PROTEINS AND PEPTIDES WITH EXTENDED ACTION AND METHODS OF PRODUCTION AND USE THEREOF
IL204111A (en) Preparations of notch fusion proteins are individualized and used
IL206184A0 (en) Systems and methods for delivery of materials
WO2008131052A9 (en) Novel peptide amphiphiles having improved solubility and methods of using same
EP2234636A4 (en) FORMULATIONS OF STABILIZED PEPTIDES AND PROTEINS
IL203221A (en) Bioactive peptides and antibodies
EP2101804B8 (en) Pro-angiogenic peptides
IL200019A0 (en) Polypeptide films and methods
GB0724953D0 (en) Methods of peptide modification
AU2008330996A1 (en) STAT3 epitope peptides
SI2041156T1 (sl) Peptidi 4-amino-4-oksobutanoila kot inhibitorji virusne replikacije
GB0725201D0 (en) Peptide fusion proteins
FI20070508A0 (fi) Peptidisubstraatti ja sen käyttö
GB0613884D0 (en) Particles of proteinaceous material
EP1978988A4 (en) REGULATION OF COMMUNICATING JUNCTIONS USING PEPTIDES
EP2121726A4 (en) PROTEIN PARTICLE